Volume : 08, Issue : 12, December – 2021
Title:
06.DEVELOPMENT AND CHARACTERIZATION OF LECITHIN-BASED NANOFORMULATION FOR ENHANCED DELIVERY OF ISONIAZID IN THE TREATMENT OF TUBERCULOSIS
Authors :
Ezegbe Chekwube Andrew, Mbah Chukwuemeka Christian, Ezegbe Amarachi Grace, Ofoefule Ifeanyi Sabinus
Abstract :
Background: Isoniazid (INH) is a synthetic antimicrobial agent used in the treatment of tuberculosis. It is rapidly and completely absorbed after oral administration. With the advent of nanoscience and nanotechnology, nanoparticles are able to encapsulate drugs, thus protecting them against the effect of chemical and enzymatic degradation. Objectives: To develop a low dose lecithin-based nano-formulation of isoniazid, to characterize some physiochemical properties of the isoniazid nanocapsules, to evaluate the antimycobacterial activities of the isoniazid nanoparticles against Mycobacterium isolates. Methods: INH nanocapsules were formulated by mechanical dispersion method. Preformulation studies were done using Fourier Transform Infra-red (FTIR) spectroscopy, DSC and Design Expert® version 13, Stat-Ease Inc; Minneapolis). The final products were made into tablets and enteric coated capsules using entrisic (Capsugel®). The nanoformulations were characterized for particle size using zeta sizer, morphology by scanning electron microscopy (SEM), thermal properties by Differential Scanning Calorimetry (DSC), entrapment efficiency (EE) and in vitro release. The in vitro anti-mycobacterium activities of the nanoformulations were assessed by the method of Pires et al., (2014) comparatively with commercial brands of INH tablets. Result: The isoniazid nanocapsules had a polydispersity index range from 0.294 ± 0.04 to 0.295 ± 0.04, while the particle size ranged from 106.0 ± 0.05 to 106.1 ± 0.05 nm. The encapsulation efficiency ranged from 95.4 ± 0.37 to 95.7 ± 0.10 %. The percentage drug content ranged from 93.5 ± 0.94 to 96.4 ± 0.29 %. The weight uniformity ranged from 0.25 ± 0.04 to 0.26 ± 0.04 g, while the disintegration time ranged from 12.3 ± 0.01 to 13.2 ± 0.01 min. The in vitro release studies showed that at 8 h, 80.5 % of drug was released in batch IRL, while 99.2 % of drug was released in batch IEL. The results of the antimycobacterial studies indicated that the MICs of the INH nanocapsule formulations (IEL and IRL), were 0.03 and 0.03 µg/ml against M. smegmatis and M. bovis, respectively, which were significantly (p < 0.05) lower than that of the conventional tablet (0.1 µg/ml). Conclusion: Chitosan-fortified lecithin-based nanocapsules containing INH were formulated using locally-extracted lecithin. The nanoformulations could be further developed for application in the treatment of MDR-TB.
Keywords: Isoniazid, Tuberculosis, Nanoparticles, Antimycobacterium studies, Nanotechnology.
Cite This Article:
Please cite this article in press Ezegbe Chekwube Andrew et al, Development And Characterization Of Lecithin-Based Nanoformulation For Enhanced Delivery Of Isoniazid In The Treatment Of Tuberculosis., Indo Am. J. P. Sci, 2021; 08(12).
Number of Downloads : 10
References:
1. Eker B, Ortmann J, Migliori G.B, Sotgiu G, Muetterlein R, Centis R, Hoffmann H, Kirsten D, Schaberg T, Ruesch-gerdes S and Lange C. Multidrug and extensively drug-resistant tuberculosis Germany. Emerging infectious Diseases, 2008; 14 (11), 1700-6.
2. Van Solingen D. A novel pathogenic taxon of the Mycobacterium tuberculosis complex. Carnetti. Characterization of an exceptional isolate. International Journal of Systemic Bacteriology. 1997; 47 (4), 1236-45.Eric A, Robert G, Eric D. Drug loaded nanoparticles. Preparation methods and drug targeting issues. Eur. J. Pharm Biopharm. 1993; 39: 73-91.
3. Hirano T, Yasuda S, Osaka Y. “The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line”. International Journal of Pharmaceutics. 2008; 351 (1-2), 113-8.
4. Thwaites G.E., Bhavnani S.M, Chau T.T. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother. 2011; 55:3244–53.
5. Global tuberculosis control and World Health Organization. Available at http//www.dx.doi.org/10.1186/1472-6904-9-1. [2012].
6. Brigger I, Dubernet C, and Couvreur P. “Nanoparticles in cancer therapy and diagnosis,”AdvancedDrugDelivery Reviews, 2002; vol. 54, no. 5, pp. 631–651.
7. J. Panyam and V. Labhasetwar. “Biodegradable nanoparticles for drug and gene delivery to cells and tissue,” Advanced Drug Delivery Reviews, 2003; vol. 55, no. 3, pp. 329–347.
8. Onyebujoh P, Zumla A, I. Ribeiro R. Rustomjee P. Mwaba M. Gomes, J and Grange M. Treatment of tuberculosis: present status and future prospects, Bull. World Health Organ. 2005; 83: 857–865.
9. WHO, Treatment of tuberculosis: guidelines for national programmes, 3rd Geneva World Health Organization, 2003.
I. Smith M. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence, Clin. Microbiol. Rev. 2003; 16: 463–496.
10. Park SK, Kim KD, Kim HT. Preparation of silica nanoparticles: determination of the optimal synthesis conditions for small and uniform particles. Coll Surf., 2002; 197:7–17.
11. Henglein A, Giersig M. Formation of colloidal silver nanoparticles: capping action of citrate. J Phys Chem., 1999; 103:9533–9539
12. Qiu S, Dong J, Chen G Preparation of Cu nanoparticles from water-in-oil micro emulsions. J Coll Interf Sci., 1999; 216:230–234.World Health Organization. . World Tuberculosis day. End TB essential. Available at
13. http://www.who.int/tb/publications. [2018].
14. World Health Organization. Global action plan on antimicrobial resistance. Available at http://www.who.int/iris/bitstream/10665/193736/1/9789241509763 [2015]
15. European Antibiotic Awareness Day. Available at http//ecdc.europa.eu/EAAD/Pages/home.asp. [2015]. Gierszewska M; Ostrowska C. Chitosan based membranes with different ionic crosslinking density for pharm and Indaplicatons. Carbohyd. Polym. 2016; 153: 501-511.
16. Qin H, Wang, Q.Q. Dong L Zhang X .Zhang Z.Y.M, Han R.Q. Reparation and characterization of magnetic Fe3O4–chitosan nanoparticles loaded with isoniazid Journal of Magnetism and Magnetic Materials, 2015; 381. 120–126.
17. Xiong XB, Binkhathlan Z, Molavi O and Lavasanifar A. Amphiphilic block co-polymers: Preparation and application in nano drug and gene delivery. Acta Biomater 2012; 8: 2017-2033.
18. Margret CR; Jayakar B; Palanisamy P. Formulation and evaluation of isoniazid and ethambutol hydrochloride combination tablet. International Research Journal of Pharmacy, 2012; 3 (2).
19. Guan J, Cheng P, Huang S, Wu J, Li Z and You X. Optimized preparation of levofloxacin-loaded chitosan nanoparticles by mechanical dispersion method. Phys. Procedia., 2011; 22:163-169.
20. Attama AA, Müller-Goymann C.C. A critical study of novel physically structured lipid matrices composed of a homolipid from caprahircus and theobroma oil. Int J Pharm., 2006; 322(1-2): 67–78.
21. Schulze D. (1996) Measuring powder flowability: A comparison of test methods. Part I. powder and bulk engineering. CSC Publishing Inc.
22. Soppimath K S. Aminabhavi T M, Kulkaarni A R. Rudzinski. W.E. Biodegradable polymeric nanoparticles as drug delivery devices. Journal control Rel., 2001; 70: 1-20
23. Yaowalak B, Ampol M, Bernd WM. Chitosan drug binding by ionic interaction. Eur. Journal Pharm. Sci., 2006; 62:267-74.
24. British Pharmacopoeia. British Pharmacopoeia, vol. III. London. Her Majesty’s Stationery Office. 6578-6585. [2009].
25. Higuchi WI, Mir NA, Desai SJ. Dissolution rate of polyphase mixtures. Pharm Sci., 1965; 54: 1405-10.
26. Palomino JC, Martin A, Camacho M, Guerra H, Swings J, Portaels F. Resazurinm crotiter assay plate: Simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother., 2002; 46: 2720-2722.
27. Pires CT, Mislane AB, Regiane B, Diogenes A, Luciana D, Vera L, Rosilene F. Anti-mycobacterium tuberculosis activity and cytotoxicity of Calophyllum brasiliense Cambess (Clusiaceae). Mem Inst. Oswaldo Cruz, Rio de Janeiro., 2014; 109 (3) : 324-329.
28. Mani G, Gopi V; Elangovan V; Rajapopalan V; Sengottuvelan B. Isoniazid loaded core shell nanoparticles derived from PLGA-PEG-PLGA tri-block copolymers. In-vitro and in-vivo drug release. Colloids Surf B. Biointerfaces, 2013; 104:107-15.
29. Gaurav K, Sadhnas S, Nusrat S, Gopal K, Samiv M. Optimisation, in-vitro-in vivo evaluation and short term tolerability of novel levofloxacin-loaded PLGA nanoparticles formulation. Journal of Phar. Sci. 2002; 101: 2165-2176.
30. Beny B, Nagaraja S, Korlakunta N, Abin A. Formulation and evaluation of levofloxacin nanoparticles by ionic gelation method. Journal of Pharmacy and Pharmaceutical Sciences, 2012; 1: 1-15.
31. Gitu Pandey, Sarita Kumari, Brahmeshwar Mistra. Preparation and characterization of isoniazid and lamivudine co-loaded polymeric microspheres, Artificial cells, Nanomedicine and Biotechnology, 2016; 44:8, 1867-1877.
32. Nobbmann U.I. (2014). Polydispersity- what does it mean for DLS and chromatography. Available online at: https//www.materials-talks.com/blog/2014/10/23/
33. Mumuni A. Momoh, Emmanuel C. Ossai, Omeje E. Chidozie, Omenigbo O. Precscila, Franklin C. Kenechukwu, Kenneth O. Ofokansi, Anthony A. Attama, Kunle O. Olobayo. A new lipid-based oral delivery system of erythromycin for prolong sustain release activity. Materials Science and Engineering, 2019; 97: 245–253.
34. Ramadoss A. B; Sathya R; Radhakrishnan R. Levofloxacin: formulation and in-vitro evaluation of alginate and chitosan nanospheres Egyptian Pharmaceutical Journalm 2015; 14:30–35
35. Rojanarat W and Nakpheng T.Levofloxacin – proliposomes-oppurtunities for use in lung tuberculosis. Pharmaceutics, 2012; 4:385–412.
36. Zhou SB, Deng XM, Li X . Investigation on a novel core-coated microspheres protein delivery system. J Control Release, 2001; 75:27-36.
37. Collins, L.A.; Franzblau, S.G. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 1997; 41, 1004-1009.
38. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated anti-tubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis, 2003; 83:373–378.